Drug Trial Radar · NCT00293644
Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy
Last checked: Nov 19, 2026Latest source record: Jul 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Feb 2006
Primary completion
Jun 2012
Study completion Jun 2015
Sponsor
- Lead sponsor
- The Hospital for Sick ChildrenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Duchesnay Inc.
- First posted
- Feb 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG.
Conditions
- Hyperemesis Gravidarum
- Pregnancy
Interventions
Diclectin®Drug
Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of severe NVP (defined by PUQE score >12), or HG (defined by PUQE score >12 plus hospitalization), as compared among the 3 groups.Time frame: Follow-up in all groups will be continued monthly until delivery. An additional follow-up telephone interview will be done at approximately 6 months post delivery.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Hospital for Sick Children
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.